New expert guidance published in the World Journal of Pediatrics provides a comprehensive framework for managing nocturnal enuresis (NE) in children, addressing a common but often undertreated condition. The consensus, developed by researchers at the Children's Hospital of Fudan University and the Chinese Cooperative Group for the Management of Pediatric NE, offers 18 recommendations that aim to standardize care and improve outcomes.
Nocturnal enuresis affects a significant number of school-age children and can have lasting effects on self-esteem and family dynamics. The condition arises from multiple factors, including excessive nighttime urine production, reduced bladder capacity, and difficulty waking to bladder signals. Despite the availability of effective treatments, underdiagnosis and inconsistent clinical practices have limited success rates. In China, regional differences in healthcare access and cultural perceptions of bedwetting have further complicated care.
The updated consensus, published in the World Journal of Pediatrics, introduces several key changes. Notably, it lowers the diagnostic threshold for NE in children aged five years and older to at least one involuntary nighttime void per month for three months, down from the previous weekly standard. This shift allows for earlier intervention, potentially preventing prolonged distress.
The framework also emphasizes a clear distinction between monosymptomatic enuresis (MNE) and non-monosymptomatic enuresis (NMNE), which includes daytime urinary symptoms such as urgency or incontinence. This classification is crucial for guiding treatment decisions. The use of voiding diaries is now a cornerstone of diagnosis, requiring patients to record fluid intake and voids over two days and seven consecutive nights. This allows clinicians to identify whether the child has nocturnal polyuria, reduced bladder capacity, or both.
For MNE, treatment is phenotype-driven: desmopressin is recommended for nocturnal polyuria, while the enuresis alarm is suggested for reduced bladder capacity. Combination therapy is advised for mixed types. For NMNE, the consensus stresses the importance of managing daytime symptoms and comorbidities first, especially constipation, which affects 36–80% of these children, before addressing nighttime wetting.
The guidelines also provide clear referral criteria. Primary care physicians can manage uncomplicated MNE, but non-responders or those with suspected NMNE should be referred to specialists for further evaluation, which may include urodynamics and lumbosacral magnetic resonance imaging. For refractory cases, defined as less than 50% improvement after three months, the consensus advises a systematic review of adherence, diary findings, and underlying causes before escalating treatment.
The authors emphasize that NE should not be treated as a single disorder. Instead, clinicians should identify the child's specific pattern, consider daytime symptoms and comorbidities, and match treatment to the likely underlying mechanism. They also highlight that apparent treatment failure should prompt a thorough re-evaluation rather than immediate escalation.
These recommendations are expected to help pediatricians and primary-care clinicians determine which children can be managed locally and which require specialist input. Clearer use of voiding diaries and symptom-based classification may reduce trial-and-error approaches, while earlier attention to conditions like constipation, sleep-disordered breathing, and ADHD could improve response rates. The framework aims to enhance coordination across levels of care, ensuring timely referral when needed.
The authors acknowledge that some recommendations reflect Chinese practice patterns and that evidence is limited for certain areas, such as desmopressin withdrawal strategies. Future research and multidisciplinary care models will be essential to further refine individualized treatment approaches.
